Journal Watch · Frontiers in Immunology · 2026
Impact of IL-6 and ferritin dynamics on clinical outcomes after anti-CD19 CAR-T cell therapy in diffuse large B-cell lymphoma patients.
Day +7 IL-6 and Day +7 ferritin showed exploratory associations with mortality.
TL;DR
Day +7 IL-6 and Day +7 ferritin showed exploratory associations with mortality.
Key findings
- Day 7 IL-6 showed the numerically highest AUC for death status, whereas Day 14 ferritin showed the numerically highest AUC for CRS.
- IL-6 was negatively correlated with albumin at Day +1, Day +7, and peak, whereas ferritin was negatively correlated with RBC count at Day +1, Day +7, and peak.<h4>Conclusion</h4>Serial IL-6 and ferritin measurements were associated with CRS-related inflammatory status.
- Day +7 IL-6 and Day +7 ferritin showed exploratory associations with mortality.
Numbers at a glance (from the abstract)
Every figure above is taken verbatim from the abstract below. Check the full text for denominators, confidence intervals and subgroup detail.
What they did
Spearman correlation was used to characterize relationships between IL-6, ferritin, and routine laboratory parameters.<h4>Results</h4>CRS occurred in 68.5% of patients, and the objective response rate was 70.4%. IL-6 levels were significantly higher in patients with CRS at day 1 (<i>P</i> = 0.003) and at peak levels (<i>P</i> = 0.005). IL-6 on day 7 was associated with mortality (OR = 1.625, 95% CI: 1.076-2.737, <i>P</i> = 0.038). Ferritin was associated with CRS at all time points and showed an exploratory association with mortality, but not with treatment response.
Full abstract (original)
Background: <h4>Background</h4>Interleukin-6 (IL-6) and ferritin are routinely monitored during chimeric antigen receptor T-cell (CAR-T) therapy; however, their temporal dynamics and outcome-specific relevance remain inadequately characterized. This study aimed to evaluate the value of IL-6 and ferritin at multiple time points in patients with diffuse large B-cell lymphoma (DLBCL) receiving anti-CD19 CAR-T therapy.<h4>Methods</h4>A total of 54 patients (median age 49.0 years; 64.8% male) were retrospectively analyzed. Post-infusion IL-6 and ferritin levels were measured on day 1, day 7, day 14, and the peak value was defined as the highest level within the first 14 days after infusion. Survival was evaluated using Cox proportional hazards regression, while logistic regression was used for binary outcomes, with Firth penalized regression performed as a sensitivity analysis.
What they did: Spearman correlation was used to characterize relationships between IL-6, ferritin, and routine laboratory parameters.<h4>Results</h4>CRS occurred in 68.5% of patients, and the objective response rate was 70.4%. IL-6 levels were significantly higher in patients with CRS at day 1 (<i>P</i> = 0.003) and at peak levels (<i>P</i> = 0.005). IL-6 on day 7 was associated with mortality (OR = 1.625, 95% CI: 1.076-2.737, <i>P</i> = 0.038). Ferritin was associated with CRS at all time points and showed an exploratory association with mortality, but not with treatment response.
Results & conclusions: Day 7 IL-6 showed the numerically highest AUC for death status, whereas Day 14 ferritin showed the numerically highest AUC for CRS. IL-6 was negatively correlated with albumin at Day +1, Day +7, and peak, whereas ferritin was negatively correlated with RBC count at Day +1, Day +7, and peak.<h4>Conclusion</h4>Serial IL-6 and ferritin measurements were associated with CRS-related inflammatory status. Day +7 IL-6 and Day +7 ferritin showed exploratory associations with mortality.
Abstract © the authors / Frontiers in Immunology (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.3389/fimmu.2026.1906304 · PubMed 42694666.
Why it matters for pharma & biotech
- Directly relevant to teams in cell therapy (CAR-T / engineered cells) — the abstract reports new data in that space, so competitive and pipeline teams should read the full text.
- Because it reports human data, it can inform indication, endpoint and comparator decisions faster than preclinical work.
- For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.
Modalities & themes detected: cell therapy (CAR-T / engineered cells)
Limitations & what to check in the full text
- This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
Frequently asked questions
What did this Frontiers in Immunology study find?
Day +7 IL-6 and Day +7 ferritin showed exploratory associations with mortality.
What type of study is this?
It is a cohort / observational clinical study, published in Frontiers in Immunology in 2026. Spearman correlation was used to characterize relationships between IL-6, ferritin, and routine laboratory parameters.<h4>Results</h4>CRS occurred in 68.5% of patients, and the objective response rate was 70.4%.
Where can I read the original paper?
The original is at the publisher via DOI 10.3389/fimmu.2026.1906304. PubMed ID: 42694666. BioStudioAI reproduces the abstract for discussion and links to the source.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/impact-of-il-6-and-ferritin-dynamics-on-clinical-outcomes-after-anti-cd1-906304/
Reading papers is step one. Analysing the data is the work.
BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.
Open BioStudioAI More guides